Welcome to CSNpharm! For Research Use Only!
ADC Linker with Payload
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN20152 | Vat-Cit-PAB-Monomethyl Dolastatin 10 | 1415329-13-3 | Vat-Cit-PAB-Monomethyl Dolastatin 10 is an antibody drug conjugate cytotoxin. |
| CSN20150 | Val-Cit-PAB-MMAF | 863971-56-6 | Val-Cit-PAB-MMAF is an antibody drug conjugate cytotoxin. |
| CSN18875 | Val-Cit-PAB-MMAE | 644981-35-1 | Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate. |
| CSN18876 | SuO-Val-Cit-PAB-MMAE | N/A | SuO-Val-Cit-PAB-MMAE consists of the ADCs linker (SuO-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), SuO-Val-Cit-PAB-MMAE is an antibody-drug conjugate. |
| CSN26869 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 | SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. |
| CSN26878 | Vipivotide tetraxetan | 1702967-37-0 | PSMA-617, also know as vipivotide tetraxetan. It is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. |
| CSN23909 | Thalidomide-NH-PEG3-propionic acid | 2138440-82-9 | Pomalidomide-PEG3-C2-carboxylic acid is a PROTAC block consist of Pomalidomide linked to PEG with a carboxylic acid functional group for conjugation reactions. |
| CSN18880 | MMAF-OMe | 863971-12-4 | MMAF-OMe is a synthetic antineoplastic agent and also used as a part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. |
| CSN18878 | 4-((S)-2-((S)-2-((S)-3-Amino-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate | 1491152-26-1 | mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate. |
| CSN26872 | MC-VC-PAB-Tubulysin M | 1639939-56-2 | MC-vc-PAB-Tubulysin M consists a cleavable ADC linker (MC-vc-PAB) and a cytotoxic tubulin inhibitor Tubulysin M (HY-N7053). Tubulysin M is a cytotoxic activity tubulysin which inhibits tubulin polymerization and leads to cell cycle arrest and apoptosis[1]. |
| CSN20149 | MC-Val-Cit-PAB-MMAF | 863971-17-9 | MC-Val-Cit-PAB-MMAF is an antibody drug conjugate cytotoxin. |
| CSN20151 | SGD-1910 | 1342820-51-2 | MC-Val-Ala-PBD is an antibody drug conjugate cytotoxin. |
| CSN26874 | MB-VC-MGBA | 932744-62-2 | MB-VC-MGBA is a drug-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC[1]. |
| CSN18877 | MAL-di-EG-Val-Cit-PAB-MMAE | 2746391-62-6 | MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate. |
| CSN20147 | DM4-SPDP | 2245698-48-8 | DM4-SPDP is an antibody drug conjugate cytotoxin. |
| CSN20148 | SPDB-DM4 | 1626359-62-3 | DM4-SPDB is an antibody drug conjugate cytotoxin. |
| CSN20154 | DM4-SMCC | 1228105-52-9 | DM4-SMCC is an antibody drug conjugate cytotoxin. |
| CSN20153 | SMCC-DM1 | 1228105-51-8 | DM1-SMCC is an antibody drug conjugate cytotoxin. |
| CSN26867 | DGN549-C | 2058075-34-4 | DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. |
| CSN26873 | DBM-MMAF | 1810001-93-4 | DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC)[1]. |
| CSN26871 | DBCO-PEG4-VC-PAB-MMAE | 2129164-91-4 | DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization[1]. |
| CSN26868 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. |
| CSN17810 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE), Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate. |
| CSN26870 | MC-DM1 | 1375089-56-7 | |
| CSN26876 | DBCO-PEG4-MMAF | 2360411-65-8 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
